Creatine-Guanidinoacetic Acid Supplementation for Sarcopenia (CREGAAS)
NCT ID: NCT04652921
Last Updated: 2022-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2020-09-15
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance
NCT03350282
Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study
NCT07285226
Impact of Carbohydrate Co-ingestion on the Post-prandial Anabolic Response of Protein in Young and Elderly Men
NCT01576848
Creatine Supplementation During Resistance Training for People Recovering From Stroke
NCT03941678
Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals
NCT06376266
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Creatine-guanidinoacetic acid
2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening
Creatine-guanidinoacetic acid
A dietary supplement provided as powder dissolved in a glass of water
Inulin
4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening
Inulin
A dietary supplement provided as powder dissolved in a glass of water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Creatine-guanidinoacetic acid
A dietary supplement provided as powder dissolved in a glass of water
Inulin
A dietary supplement provided as powder dissolved in a glass of water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Free of acute disorders
Exclusion Criteria
65 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Novi Sad, Faculty of Sport and Physical Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Applied Bioenergetics Lab at Faculty of Sport and PE
Novi Sad, Vojvodina, Serbia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DS-04/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.